NASDAQ: TNYATenaya Therapeutics Inc Stock
$1.88+0.02 (+1.08%)
Updated Nov 30, 2023
TNYA Price
$1.88
Fair Value Price
N/A
Market Cap
$128.05M
52 Week Low
$1.64
52 Week High
$8.09
P/E
-1.02x
P/B
0.78x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$127.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$103M
Beta
1.76
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TNYA Overview
Tenaya Therapeutics Incorporated is a biotechnology company that develops heart diseases therapies in the U.S. It uses cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic Hypertrophic Cardiomyopathy, and TN-301, a small molecule inhibitor of Histone Deacetylase 6 (HDAC6i) for use in heart gFailure with preserved ejection fraction (HFpEF), as well as genetic Dilated Cardiomyopathy (gDCM). The company was incorporated in 2016 and is headquartered in San Francisco, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TNYA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TNYA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TNYA is good value based on its book value relative to its share price (0.78x), compared to the US Biotechnology industry average (5.4x)
P/B vs Industry Valuation
TNYA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TNYA due diligence checks available for Premium users.
Be the first to know about important TNYA news, forecast changes, insider trades & much more!
TNYA News
Valuation
TNYA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.02x
Industry
12.22x
Market
29.24x
TNYA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.78x
Industry
5.4x
TNYA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TNYA's financial health
Profit margin
Revenue
$0.0
Net Income
-$29.1M
Profit Margin
0%
TNYA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$193.4M
Liabilities
$28.5M
Debt to equity
0.17
TNYA's short-term assets ($126.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TNYA's short-term assets ($126.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TNYA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.6M
Investing
$30.5M
Financing
$0.0
TNYA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TNYA vs Biotech Stocks
Tenaya Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.